Barclays raised the firm’s price target on Keurig Dr Pepper to $40 from $37 and keeps an Overweight rating on the shares. While the potential for a guidance cut came up on several occasions during investor conversations heading into Keurig’s earnings print, the company instead posted a Q2 beat and raised its fiscal 2023 top line and underlying profit guidance, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KDP:
- Unusually active option classes on open July 27th
- Keurig Dr Pepper Reports Q2 2023 Results, Raises Full Year Net Sales Outlook and Reaffirms EPS Guidance
- Keurig Dr Pepper backs FY23 adjusted EPS growth 6%-7%, consensus $1.78
- Keurig Dr Pepper reports Q2 adjusted EPS 42c, consensus 40c
- Notable companies reporting before tomorrow’s open